

Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other) And Region – Global Analysis of Market Size, Share & Trends for 2019–2020 And Forecasts to 2031

<https://marketpublishers.com/r/U2E0DBB895CDEN.html>

Date: May 2023

Pages: 324

Price: US\$ 4,950.00 (Single User License)

ID: U2E0DBB895CDEN

Abstracts

Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other) And Region – Global Analysis of Market Size, Share & Trends for 2019–2020 And Forecasts to 2031

PRODUCT OVERVIEW

UTI (Urinary tract infection) is among the most common health problems. Because women encounter health issues such as menstruation, pregnancy, and some birth control side effects, UTI is much more common among women than in males. A person who has diabetes and then develops urological health problems is inextricably linked. Diabetes exacerbates health problems and increases the chance of UTIs, as well as bladder problems. Diabetes can also cause and result in the worsening of complications such as urologic difficulties and diseases. This is due to the fact that they are known to affect an individual's blood flow, neuron functions, and sensory processes.

MARKET HIGHLIGHTS

Global Urinary Tract Infection Therapeutics market is expected to project a notable CAGR of 3.7% in 2031.

Global Urinary Tract Infection Therapeutics to surpass USD 10.6 billion by 2031 from USD 7.4 billion in 2021 at a CAGR of 3.7% in the coming years, i.e., 2021-31. As the prevalence of diabetes & kidney stones rises, so does the majority of cases of urinary tract infection, which drives up medicine demand and hence propels the worldwide urinary infection therapeutic market.

GLOBAL URINARY TRACT INFECTION THERAPEUTICS: SEGMENTS

Uncomplicated UTI segment to grow with the highest CAGR during 2021-31

Based on indication global Urinary Tract Infection Therapeutics is categorized into Complicated UTI, Uncomplicated UTI and Other. The uncomplicated UTI market accounts the highest market growth. The most frequent type of UTI now impacting the worldwide population is uncomplicated UTIs. Antibiotics are usually prescribed to treat UTIs. Because of the rising number of hospital-acquired infections, particularly catheter-associated UTIs, the uncomplicated UTI category is expected to lead the global urinary tract infection therapies in the coming year.

Quinolones segment to grow with the highest CAGR during 2021-31

Global Urinary Tract Infection Therapeutics is segmented in the basis of Drug type into Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other. The quinolones category retained the greatest share of the market, which also consist of penicillin and combination sector is expected to grow at the fastest rate over the forecast period. As they are available in hospital and retail pharmacies. The fact that quinolones are routinely recommended by physicians is largely responsible for the market's future growth. Fluoroquinolones, ofloxacin, & enoxacins are among the most commonly prescribed antibiotics

MARKET DYNAMICS

Drivers

Increasing in prevalence of UTIs

Rising demand for Antibiotic consumption

Restraint

Complicated legal obligations

GLOBAL URINARY TRACT INFECTION THERAPEUTICS:

Key Players

Allergan

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

Bayer AG

Pfizer, Inc.

GlaxoSmithKline plc

Bristol-Myers Squibb Company

Janssen Global Services, LLC

Lupin Ltd.

Merck & Co., Inc

Almirall, S.A

Other Prominent Players

GLOBAL URINARY TRACT INFECTION THERAPEUTICS: REGIONS

Global Urinary Tract Infection Therapeutics market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The North American region includes countries that results in the growth of the global urine tract infection therapeutic market. The North American

Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Ty...

market is anticipating a significant increase in investment in research & development of treatment goods and diagnostics that will aid in the global expansion of the urinary tract infection (UTI) industry. Because of the expanding prevalence of Urinary infections and renal issues among the populations of this region, the United States has a growing global market share.

IMPACT OF COVID-19 ON URINARY TRACT INFECTION THERAPEUTICS MARKET

The unexpected rise of coronavirus-infected patients hampered access to other primary care treatments, resulting in a large decline in non-COVID-19-related diagnoses such urinary tract infection. In 2020, the rate of UTI diagnostic decreased somewhat, possibly slowing the industry's expansion in recent months. A considerable decline in urinary infection (UTI) diagnosis associated to the COVID-19 pandemic is cause for concern. As a result, fewer people sought primary care services, and fewer diagnoses, such as UTIs.

GLOBAL URINARY TRACT INFECTION THERAPEUTICS REPORT ALSO CONTAINS ANALYSIS ON:

Urinary Tract Infection Therapeutics Segments:

By Indication

Complicated UTI,

Uncomplicated UTI

Other

By Drug Type

Quinolones

Cephalosporin

Azoles

Amphotericin B

Nitro furans

Other

Urinary Tract Infection Therapeutics Dynamics

Urinary Tract Infection Therapeutics Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies Involved in the Market

Value Chain of the Market

Market Drivers and Restraints

Reasons to Purchase this Report

Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights,

product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market of various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

3-month post-sales analyst support.

Contents

1.EXECUTIVE SUMMARY

- 1.1. Regional Market Share
- 1.2. Business Trends
- 1.3. Global Urinary Tract Infection Therapeutics Market: COVID-19 Outbreak
- 1.4. Regional Trends
- 1.5. Segmentation Snapshot

2 RESEARCH METHODOLOGY

- 2.1. Research Objective
- 2.2. Research Approach
- 2.3. Data Sourcing and Methodology
- 2.4. Primary Research
- 2.5. Secondary Research
 - 2.5.1. Paid Sources
 - 2.5.2. Public Sources
- 2.6. Market Size Estimation and Data Triangulation

3 MARKET CHARACTERISTICS

- 3.1. Market Definition
- 3.2. Global Urinary Tract Infection Therapeutics Market: COVID-19 Impact
- 3.3. Key Segmentations
- 3.4. Key Developments
- 3.5. Allied Industry Data

4 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET – INDUSTRY INSIGHTS

- 4.1. Industry Segmentation
- 4.2. COVID-19 overview on world economy
- 4.3. Industry ecosystem Channel analysis
- 4.4. Innovation & Sustainability

5 MACROECONOMIC INDICATORS

6 RECENT DEVELOPMENTS

7 MARKET DYNAMICS

- 7.1. Introduction
- 7.2. Growth Drivers
- 7.3. Market Opportunities
- 7.4. Market Restraints
- 7.5. Market Trends

8 RISK ANALYSIS

9 MARKET ANALYSIS

- 9.1. Porters Five Forces
- 9.2. PEST Analysis
 - 9.2.1. Political
 - 9.2.2. Economic
 - 9.2.3. Social
 - 9.2.4. Technological

10 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET

- 10.1. Overview
- 10.2. Historical Analysis (2016-2020)
 - 10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

11 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

- 11.1. Overview
- 11.2. Key Findings
- 11.3. Market Segmentation
 - 11.3.1. By Indication
 - 11.3.1.1. Complicated UTI
 - 11.3.1.1.1. By Value (USD Million) 2021-2031F
 - 11.3.1.1.2. Market Share (%) 2021-2031F
 - 11.3.1.1.3. Y-o-Y Growth (%) 2021-2031F
 - 11.3.1.2. Uncomplicated UTI

- 11.3.1.2.1. By Value (USD Million) 2021-2031F
- 11.3.1.2.2. Market Share (%) 2021-2031F
- 11.3.1.2.3. Y-o-Y Growth (%) 2021-2031F
- 11.3.1.3. Other
 - 11.3.1.3.1. By Value (USD Million) 2021-2031F
 - 11.3.1.3.2. Market Share (%) 2021-2031F
 - 11.3.1.3.3. Y-o-Y Growth (%) 2021-2031F
- 11.3.2. By Drug Type
 - 11.3.2.1. Quinolones
 - 11.3.2.1.1. By Value (USD Million) 2021-2031F
 - 11.3.2.1.2. Market Share (%) 2021-2031F
 - 11.3.2.1.3. Y-o-Y Growth (%) 2021-2031F
 - 11.3.2.2. Cephalosporin
 - 11.3.2.2.1. By Value (USD Million) 2021-2031F
 - 11.3.2.2.2. Market Share (%) 2021-2031F
 - 11.3.2.2.3. Y-o-Y Growth (%) 2021-2031F
 - 11.3.2.3. Azoles and Amphotericin B
 - 11.3.2.3.1. By Value (USD Million) 2021-2031F
 - 11.3.2.3.2. Market Share (%) 2021-2031F
 - 11.3.2.3.3. Y-o-Y Growth (%) 2021-2031F
 - 11.3.2.4. Nitro furans
 - 11.3.2.4.1. By Value (USD Million) 2021-2031F
 - 11.3.2.4.2. Market Share (%) 2021-2031F
 - 11.3.2.4.3. Y-o-Y Growth (%) 2021-2031F
 - 11.3.2.5. Other
 - 11.3.2.5.1. By Value (USD Million) 2021-2031F
 - 11.3.2.5.2. Market Share (%) 2021-2031F
 - 11.3.2.5.3. Y-o-Y Growth (%) 2021-2031F

12 NORTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

- 12.1. Overview
- 12.2. Key Findings
- 12.3. Market Segmentation
 - 12.3.1. By Indication
 - 12.3.2. By Drug Type
- 12.4. Country
 - 12.4.1. United States

12.4.2. Canada

13 EUROPE URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

13.1. Overview

13.2. Key Findings

13.3. Market Segmentation

13.3.1. Indication

13.3.2. By Drug Type

13.4. Country

13.4.1. Germany

13.4.2. United Kingdom

13.4.3. France

13.4.4. Italy

13.4.5. Spain

13.4.6. Russia

13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

14 ASIA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

14.1. Overview

14.2. Key Findings

14.3. Market Segmentation

14.3.1. By Indication

14.3.2. By Drug Type

14.4. Country

14.4.1. India

14.4.2. China

14.4.3. South Korea

14.4.4. Japan

14.4.5. Rest of APAC

15 MIDDLE EAST AND AFRICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

15.1. Overview

15.2. Key Findings

15.3. Market Segmentation

15.3.1. By Indication

15.3.2. By Drug Type

15.4. Country

15.4.1. Israel

15.4.2. GCC

15.4.3. North Africa

15.4.4. South Africa

15.4.5. Rest of Middle East and Africa

16 LATIN AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F

16.1. Overview

16.2. Key Findings

16.3. Market Segmentation

16.3.1. By Indication

16.3.2. By Drug Type

16.4. Country

16.4.1. Mexico

16.4.2. Brazil

16.4.3. Rest of Latin America

17 COMPETITIVE LANDSCAPE

17.1. Company market share, 2021

17.2. Key player overview

17.3. Key stakeholders

18 COMPANY PROFILES

18.1. Allergan

18.1.1. Company Overview

18.1.2. Financial Overview

18.1.3. Key Product; Analysis

18.1.4. Company Assessment

18.1.4.1. Product Portfolio

18.1.4.2. Key Clients

18.1.4.3. Market Share

18.1.4.4. Recent News & Development (Last 3 Yrs.)

18.1.4.5. Executive Team

18.2. Bayer AG

18.3. Pfizer, Inc.

18.4. GlaxoSmithKline plc

18.5. Bristol-Myers Squibb Company

18.6. Janssen Global Services, LLC

18.7. Lupin Ltd.

18.8. Merck & Co., Inc

18.9. Almirall, S.A

18.10. Other Prominent Players

19 APPENDIX

20 CONSULTANT RECOMMENDATION

I would like to order

Product name: Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans and Other) And Region – Global Analysis of Market Size, Share & Trends for 2019–2020 And Forecasts to 2031

Product link: <https://marketpublishers.com/r/U2E0DBB895CDEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U2E0DBB895CDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970